Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)

Home Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)

Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)

/ Publications

Share the Post

About the Author

Related Posts

Read More
Scott Giacobello, CPA
Read More
Stephen Rodin, JD
Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)
Mohammad Hirmand, MD
Study-end analysis from AMPECT, an open-label, phase 2 registration trial of patients with advanced malignant PEComatreated with nab-sirolimus, showing durability of response and long-term safety
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
Synergistic Antitumor Activity of nab-Sirolimus in Combination With KRAS Inhibitors Sotorasib and Adagrasib in KRAS G12C Non-Small Cell Lung Cancer and Bladder Cancer Xenografts
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2

Comments

Comments are closed.